Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

DRUGSCAN, INC.

NPI: 1649418351 · HORSHAM, PA 19044 · Clinical Medical Laboratory · NPI assigned 02/03/2009

$48.28M
Total Medicaid Paid
1,963,232
Total Claims
1,400,863
Beneficiaries
98
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialCOSTANTINO, ANTHONY (PRESIDENT/CEO)
Parent OrganizationTOXICLOGY HOLDINGS CORP
NPI Enumeration Date02/03/2009

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 101,537 $2.05M
2019 125,468 $2.06M
2020 127,744 $2.83M
2021 311,971 $8.11M
2022 389,864 $10.88M
2023 457,552 $10.89M
2024 449,096 $11.45M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 614,260 425,200 $22.22M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 323,536 237,720 $15.75M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 86,628 57,599 $4.69M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 28,597 18,386 $1.77M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 16,387 10,625 $1.24M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 5,610 3,669 $398K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 17,197 11,495 $314K
80348 75,166 52,557 $251K
80324 50,725 37,328 $215K
80323 44,332 24,475 $172K
80349 53,993 40,543 $153K
80346 38,295 30,567 $145K
80362 81,184 54,971 $118K
80355 71,206 44,928 $104K
80321 26,172 21,992 $79K
80372 37,400 31,138 $77K
80356 21,268 19,290 $59K
80361 21,134 19,159 $48K
80366 41,095 29,259 $34K
80365 14,513 13,237 $26K
80352 14,591 8,137 $25K
80353 12,829 10,820 $25K
80371 31,911 17,786 $22K
80357 9,849 7,480 $21K
80354 13,099 10,697 $20K
80358 10,337 8,534 $19K
80332 8,273 6,542 $19K
80320 4,016 3,359 $17K
80368 11,374 9,244 $17K
80360 30,379 19,443 $15K
80373 4,044 3,655 $14K
84311 23,780 18,885 $14K
80338 6,192 4,379 $12K
80375 6,680 4,255 $11K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 946 860 $11K
80335 3,221 2,649 $11K
82570 23,821 18,916 $10K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 237 209 $10K
80053 Comprehensive metabolic panel 1,411 1,270 $7K
80369 16,802 11,525 $7K
83986 23,810 18,901 $6K
80359 4,890 4,170 $6K
80345 2,486 2,325 $6K
84443 Thyroid stimulating hormone (TSH) 789 715 $6K
80061 Lipid panel 819 752 $5K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 340 292 $5K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 339 292 $5K
86780 537 529 $5K
82652 132 129 $5K
86803 634 584 $4K
80342 12,805 7,544 $4K
81025 1,437 1,262 $4K
86708 550 521 $4K
82607 507 464 $4K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 346 322 $3K
83992 554 520 $3K
80074 229 208 $3K
86704 513 501 $3K
87340 511 483 $3K
86709 421 411 $2K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 927 877 $2K
80374 1,820 1,557 $2K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 96 88 $2K
87522 Neg quan hep c or qual rna 43 42 $2K
86706 224 222 $1K
83036 Hemoglobin; glycosylated (A1C) 431 373 $1K
86696 87 87 $1K
81001 524 492 $950.95
84315 1,122 1,020 $796.00
86140 237 217 $628.08
83735 116 114 $553.26
84439 72 68 $520.44
82746 173 125 $451.46
86804 70 70 $427.93
80050 General health panel 12 12 $421.56
86038 112 95 $370.74
86695 69 69 $326.51
82248 157 155 $299.15
83540 137 124 $289.06
84436 197 173 $286.57
87086 Culture, bacterial; quantitative colony count, urine 51 47 $275.25
84403 15 15 $248.76
82728 61 58 $222.77
84481 25 25 $211.99
84479 152 136 $194.11
83550 79 68 $189.48
82150 110 93 $176.78
82550 56 50 $170.95
80339 445 274 $154.34
86431 95 83 $150.99
84153 36 28 $123.38
84550 75 69 $108.51
85652 92 83 $75.25
87088 13 12 $61.17
84154 18 17 $58.85
86705 23 12 $32.84
83721 109 93 $22.74
85027 12 12 $3.84